查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
亚太地区多重癌症检测市场 – 分析与预测（2023-2032）
市场调查报告书
商品编码
1385469

亚太地区多重癌症检测市场 – 分析与预测（2023-2032）

Asia-Pacific Multicancer Screening Market - Analysis and Forecast, 2023-2032
出版日期: | 出版商: BIS Research | 英文 95 Pages | 商品交期: 1-5个工作天内

价格

截至 2022 年，亚太地区多重癌症检测市场规模价值 2.7 亿美元，预计到 2032 年将达到 14 亿美元。

癌症发生率的上升和液体活检检测的使用增加预计将推动亚太地区多重癌症检测市场的扩张。

主要市场统计数据
预测期 2023-2032
2023年评估 3.2亿美元
2032年预测 14亿美元
年复合成长率 17.6%

亚太地区 (APAC) 的多重癌症检测市场预计将出现显着增长，因为该地区专注于改善医疗基础设施并解决各种恶性发病率不断上升的问题。随着人们越来越认识到早期检测在改善治疗结果方面发挥的重要作用，使用先进诊断技术同时检测多种癌症类型的多癌症检测在亚太地区变得越来越普及。该市场是由倡议预防和控制倡议的增加、高龄化以及筛检技术的技术突破所推动的。随着亚太地区政府和医疗机构更加重视实施全面的癌症筛检计划，多重癌症检测市场正在不断成长。随着对更容易获得和更准确的癌症诊断的需求的增加，亚太地区多重癌症检测市场预计将成长。

本报告研究了亚太地区多重癌症检测市场，概述了市场、国家趋势以及参与该市场的公司概况。

目录

第1章市场

  • 产品定义
  • 纳入与排除标准
  • 市场范围
  • 调查方法

第2章市场概况

  • 市场概况
  • 多种癌症检测的工作流程分析
  • 市场足迹和成长潜力
  • 未来性
  • COVID-19 对市场的影响

第3章业界考察

  • 专利分析
  • 赎回场景
  • 供应链分析
  • 价格分析（按测试类型）

第4章市场动态

  • 概述
  • 影响分析
  • 市场驱动力
  • 市场挑战
  • 市场机会

第5章竞争形势

  • 关键策略和发展
  • 市场占有率分析（2022）
  • 成长份额分析（2022）

第6章亚太地区

  • 概述
  • 亚太地区

第7章市场-公司简介

  • 概述
  • 多种癌症检测市场的市场价值链
  • 参与企业
  • Burning Rock DX
  • Genecast Biotechnology Co., Ltd
  • Konica Minolta, Inc. (Ambry Genetics.)
Product Code: BHP1532SS

“The Asia-Pacific Multicancer Screening Market Expected to Reach $1.40 Billion by 2032.”

Introduction to Asia-Pacific (APAC) Multicancer Screening Market

As of 2022, the Asia-Pacific multicancer screening market was valued at $0.27 billion and is expected to attain a value of $1.40 billion by 2032. The rising incidence of cancer and growing use of liquid biopsy testing are anticipated to fuel market expansion for multicancer screening in Asia-Pacific.

KEY MARKET STATISTICS
Forecast Period2023 - 2032
2023 Evaluation$0.32 Billion
2032 Forecast$1.40 Billion
CAGR17.6%

Market Introduction

The market for multicancer screening in Asia-Pacific (APAC) is expected to develop significantly as the area concentrates on improving healthcare infrastructure and tackling the increased incidence of different malignancies. The practice of multicancer screening, which is the simultaneous detection of numerous cancer types by sophisticated diagnostic techniques, is becoming more and more popular throughout Asia-Pacific as people become more aware of the critical role that early detection plays in enhancing treatment outcomes. The market is being pushed by increasing initiatives for cancer prevention and control, an aging population, and technical breakthroughs in screening technologies. The multicancer screening market is growing as a result of governments and healthcare organizations in the Asia-Pacific area placing a strong emphasis on the adoption of comprehensive cancer screening programs. The market for APAC multicancer screening is expected to grow as demand increases for more accessible and precise cancer diagnosis.

Market Segmentation

Segmentation 1: by Country

  • China
  • Japan
  • India
  • Australia
  • South Korea
  • Rest-of-Asia-Pacific

In 2021, China was the leading contributor to the Asia-Pacific multicancer screening market, with a market share of 32.64%. Japan is the second-largest contributor to the Asia-Pacific multicancer screening market.

How can this report add value to an organization?

Product/Innovation Strategy: The report considers multicancer screening kit/panel and assay product-based companies. The industry is seeing constant development and product launches with new and innovative upgrades. Additionally, new discoveries of specific biomarkers related to various cancer types are increasing researchers' trust in multicancer sequencing.

Growth/Marketing Strategy: The key components in multicancer screening are the kits and the related technologies for sample analysis. The advancements in new analysis methods like liquid biopsy are influencing the growth of this market. Additionally, the discovery of biomarkers and other genes for various diseases is helping panel manufacturers curate precise kits and assays for multicancer screening of various cancer types.

Competitive Strategy: The key players in the Asia-Pacific multicancer screening market have been analyzed and profiled in the study, consisting of most product-based companies, as well as a few emerging companies. Moreover, a detailed competitive benchmarking of the players operating in the Asia-Pacific multicancer screening market has been done to help the reader understand how players stack against each other, presenting a clear market landscape. Additionally, comprehensive competitive strategies such as partnerships, agreements, and collaborations will aid the reader in understanding the untapped revenue pockets in the market.

Key Market Players and Competition Synopsis

The companies that are profiled have been selected based on inputs gathered from primary experts, analyzing company coverage, product portfolio, and market penetration.

Some of the prominent names established in this market are:

  • Burning Rock DX
  • Genecast Biotechnology Co., Ltd.
  • Konica Minolta, Inc. (Ambry Genetics.)

Table of Contents

1 Markets

  • 1.1 Product Definition
  • 1.2 Inclusion and Exclusion Criteria
  • 1.3 Market Scope
    • 1.3.1 Scope of the Study
    • 1.3.2 Key Questions Answered in the Report
  • 1.4 Research Methodology
    • 1.4.1 Asia-Pacific Multicancer Screening Market: Research Methodology
    • 1.4.2 Data Sources
    • 1.4.3 Market Estimation Model
    • 1.4.4 Criteria for Company Profiling

2 Market Overview

  • 2.1 Market Overview
  • 2.2 Multicancer Screening Workflow Analysis
  • 2.3 Market Footprint and Growth Potential
  • 2.4 Future Potential
  • 2.5 COVID-19 Impact on the Market

3 Industry Insights

  • 3.1 Patent Analysis
    • 3.1.1 Patent Filing Trend
    • 3.1.2 Patent Analysis (by Country)
    • 3.1.3 Patent Analysis (by Region)
  • 3.2 Reimbursement Scenario
  • 3.3 Supply Chain Analysis
  • 3.4 Pricing Analysis (by Test Type)

4 Market Dynamics

  • 4.1 Overview
  • 4.2 Impact Analysis
  • 4.3 Market Drivers
    • 4.3.1 Early Detection of Cancer Leads to Higher Survival Chances and Better Treatment
    • 4.3.2 Increasing Popularity of Liquid Biopsy Leading to Easier Screening
    • 4.3.3 Reduced Treatment Cost Due to Earlier Cancer Detection
  • 4.4 Market Challenges
    • 4.4.1 Lack of Awareness about the Multicancer Screening Tests
    • 4.4.2 Too Costly to be Used as Preventive Care
  • 4.5 Market Opportunities
    • 4.5.1 Robust Pipeline of Multicancer Screening Tests Poised to Revolutionize Cancer Diagnosis
    • 4.5.2 New Biomarkers being Discovered Regularly

5 Competitive Landscape

  • 5.1 Key Strategies and Developments
    • 5.1.1 Mergers and Acquisitions
    • 5.1.2 Synergistic Activities
    • 5.1.3 Product Launches and Upgradations
    • 5.1.4 Funding and Expansion
  • 5.2 Market Share Analysis (2022)
  • 5.3 Growth-Share Analysis (2022)
    • 5.3.1 Growth-Share Analysis (by Technology)

6 Asia-Pacific

  • 6.1 Overview
  • 6.2 Asia-Pacific
    • 6.2.1 China
    • 6.2.2 Japan
    • 6.2.3 India
    • 6.2.4 Australia
    • 6.2.5 South Korea
    • 6.2.6 Rest-of-Asia-Pacific

7 Markets - Company Profiles

  • 7.1 Overview
  • 7.2 Market Value Chain of Multicancer Screening Market
  • 7.3 Multicancer Screening Ecosystem Active Players
  • 7.4 Burning Rock DX
    • 7.4.1 Company Overview
    • 7.4.2 Role of Burning Rock DX in the Asia-Pacific Multicancer Screening Market
    • 7.4.3 Key Competitors of the Company
    • 7.4.4 Business Strategies
    • 7.4.5 Analyst Perspective
  • 7.5 Genecast Biotechnology Co., Ltd
    • 7.5.1 Company Overview
    • 7.5.2 Role of Genecast Biotechnology Co., Ltd in the Asia-Pacific Multicancer Screening Market
    • 7.5.3 Key Competitors of the Company
    • 7.5.4 Analyst Perspective
  • 7.6 Konica Minolta, Inc. (Ambry Genetics.)
    • 7.6.1 Company Overview
    • 7.6.2 Role of Konica Minolta, Inc. (Ambry Genetics.) in the Asia-Pacific Multicancer Screening Market
    • 7.6.3 Key Competitors of the Company
    • 7.6.4 Financials
    • 7.6.5 Analyst Perspective

List of Figures

  • Figure 1: Asia-Pacific Multicancer Screening Market, $Billion, 2022 and 2032
  • Figure 2: Share of Asia-Pacific Multicancer Screening Market (by Test Type), $Billion, 2021 and 2032
  • Figure 3: Share of Asia-Pacific Multicancer Screening Market (by Sample), $Billion, 2021 and 2032
  • Figure 4: Share of Asia-Pacific Multicancer Screening Market (by Cancer Type), $Billion, 2021 and 2032
  • Figure 5: Share of Multicancer Screening Market (by Region), 2022
  • Figure 6: Asia-Pacific Multicancer Screening Market Segmentation
  • Figure 7: Asia-Pacific Multicancer Screening Market: Research Methodology
  • Figure 8: Primary Research Methodology
  • Figure 9: Bottom-Up Approach (Segment-Wise Analysis)
  • Figure 10: Top-Down Approach (Segment-Wise Analysis)
  • Figure 11: Multicancer Screening Workflow, End User Perspective
  • Figure 12: Multicancer Screening Workflow, Laboratory Technician Perspective
  • Figure 13: Asia-Pacific Multicancer Screening Market, $Billion, 2021-2032
  • Figure 14: COVID-19 Impact
  • Figure 15: Asia-Pacific Multicancer Screening Market, Patent Analysis (by Year), January 2020-December 2022
  • Figure 16: Multicancer Screening Market, Patent Analysis (by Country), January 2020-December 2022
  • Figure 17: Multicancer Screening Market, Patent Analysis (by Region), January 2020-December 2022
  • Figure 18: Supply Chain Analysis of the Multicancer Screening Market
  • Figure 19: Asia-Pacific Multicancer Screening Market Dynamics
  • Figure 20: Prevalence vs. Age-Standardized Death Rate of Cancer Globally, 2010-2019 (%)
  • Figure 21: Liquid Biopsy vs. Tissue Biopsy
  • Figure 22: Liquid Biopsy Clinical Trials (by Cancer Types), Share (%), 2023
  • Figure 23: Out-of-Pocket Costs for Complete Treatment by Cancer Type and Stage Among Insured Patient, ($)
  • Figure 24: Lead-Time Bias in Cancer Screening
  • Figure 25: Screened vs. Non-Screened Cancer Patients per 1,000,000 Incidence Rate (50-79 Years)
  • Figure 26: Multicancer Early Detection Tests + Usual Care Screening Costs vs. only Usual Care Screening Costs
  • Figure 27: Share of Key Developments and Strategies, January 2020-January 2023
  • Figure 28: Synergistic Activities Share (by Company), January 2020- January 2023
  • Figure 29: Product Launches and Upgradations (by Company), January 2020-January 2023
  • Figure 30: Market Share Analysis for Asia-Pacific Multicancer Screening Market, $Billion, 2022
  • Figure 31: Growth-Share Analysis of the Asia-Pacific Multicancer Screening Market (by Technology), 2022
  • Figure 32: Multicancer Screening Market Snapshot (by Region), $Billion, 2022
  • Figure 33: Multicancer Screening Market (by Region), $Billion, 2021-2032
  • Figure 34: Asia-Pacific Multicancer Screening Market, $Billion, 2021-2032
  • Figure 35: Asia-Pacific Multicancer Screening Market Share (by Country), $Million, 2021-2032
  • Figure 36: China Multicancer Screening Market, $Million, 2021-2032
  • Figure 37: Japan Multicancer Screening Market, $Million, 2021-2032
  • Figure 38: India Multicancer Screening Market, $Million, 2021-2032
  • Figure 39: Australia Multicancer Screening Market, $Million, 2021-2032
  • Figure 40: South Korea Multicancer Screening Market, $Million, 2021-2032
  • Figure 41: Rest-of-Asia-Pacific Multicancer Screening Market, $Million, 2021-2032
  • Figure 42: Multicancer Screening Market, Total Number of Companies Profiled
  • Figure 43: Multicancer Screening Market: Value Chain
  • Figure 44: Burning Rock DX: Product Portfolio
  • Figure 45: Genecast Biotechnology Co., Ltd: Product Portfolio
  • Figure 46: Konica Minolta, Inc. (Ambry Genetics.): Product Portfolio
  • Figure 47: Konica Minolta, Inc. (Ambry Genetics.): Overall Financials, $Million, 2019-2021
  • Figure 48: Konica Minolta, Inc. (Ambry Genetics.): Revenue (by Segment), $Million, 2019-2021
  • Figure 49: Konica Minolta, Inc. (Ambry Genetics.): Revenue (by Region), $Million, 2019-2021
  • Figure 50: Konica Minolta, Inc. (Ambry Genetics.): R&D Expenditure, $Million, 2019-2021

List of Tables

  • Table 1: Impact Analysis of Market Drivers, Challenges, and Opportunities on the Asia-Pacific Multicancer Screening Market
  • Table 2: Technological Trends in Asia-Pacific Multicancer Screening Market
  • Table 3: Average Prices of Multicancer Screening Kits Calculation
  • Table 4: Likert Scale
  • Table 5: Impact Analysis of Market Drivers
  • Table 6: Impact Analysis of Market Challenges
  • Table 7: Five-Year Survival Rates for Different Cancers at Different Stages
  • Table 8: Top Multicancer Screening Tests and Their Costs ($)
  • Table 9: Asia-Pacific Multicancer Screening Market, Pipeline Tests
  • Table 10: Cancers and Their Most Common Biomarker Tests